Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03418038 · ClinicalTrials.gov registry record · Phase 2
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
A Phase 2 study of Chronic Myelomonocytic Leukemia and Recurrent Diffuse Large B-Cell Lymphoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 4
- Study locations
NCT03418038 is a Phase 2 study of Chronic Myelomonocytic Leukemia and Recurrent Diffuse Large B-Cell Lymphoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 80 participants, roughly in line with the 88-participant average among 73 other Chronic Myelomonocytic Leukemia trials with a reported enrollment target. The trial reports 4 study locations across 2 states.
The verdict
NCT03418038, a Phase 2 study of Chronic Myelomonocytic Leukemia and Recurrent Diffuse Large B-Cell Lymphoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 4
- Study locations
Study Summary
This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined significance and chronic myelomonocytic leukemia (CMML). Ascorbic acid may make cancer cells more sensitive to chemotherapy. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ascorbic acid and combination chemotherapy may kill more cancer cells.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Dexamethasone
- DRUG Cytarabine
- DIETARY_SUPPLEMENT Ascorbic Acid
Study Locations (4)
Minnesota
- Mayo Clinic Health Systems-Mankato - Mankato
- Mayo Clinic in Rochester - Rochester
Wisconsin
- Mayo Clinic Health System-Eau Claire Clinic - Eau Claire
- Mayo Clinic Health System-Franciscan Healthcare - La Crosse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2018-03-23 |
| Est. Completion | 2033-11-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03418038
The ClinicalTrials.gov registry entry for NCT03418038 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 88-participant average among 73 other Chronic Myelomonocytic Leukemia trials with a reported enrollment target. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Chronic Myelomonocytic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT03418038 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Minnesota, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03418038 about?
NCT03418038 is a clinical study titled "Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia". This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined significance and chronic myelomonocytic leukemia (CMML). Ascorbic acid ...
What is the current status of trial NCT03418038?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2018-03-23. Estimated completion is 2033-11-02.
What conditions does trial NCT03418038 study?
This clinical trial studies the following conditions: Chronic Myelomonocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Clonal Cytopenia of Undetermined Significance.
What interventions are being tested in trial NCT03418038?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Dexamethasone (DRUG), Cytarabine (DRUG), Ascorbic Acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03418038?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03418038 being conducted?
This trial has 4 study locations across Minnesota, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myelomonocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
RECRUITING · Phase 2
-
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RECRUITING · Phase 2
-
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
RECRUITING · Phase 2
-
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
RECRUITING · Phase 2
Explore more on PlainTrial
Chronic Myelomonocytic Leukemia
All registered trials for this condition
Recurrent Diffuse Large B-Cell Lymphoma
All registered trials for this condition
Minnesota
All trials with a study site in Minnesota
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.